drug
letermovir
Marketedupdated 3mo agoby Merck Sharp & Dohme Corp (Inactive)
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 3all catalysts(1)
Trials studying letermovir
- phase4Letermovir for R+ Study
- phase1A Clinical Study of Letermovir (MK-8228) in Children and Adolescents Who Receive a Kidney Transplant (KT) (MK-8228-077)
- phase2Letermovir for CMV Prevention After Lung Transplantation
- phase3De-novo Initiation of Letermovir vs Valganciclovir for Cytomegalovirus Prophylaxis in AA Kidney Transplant Recipients
- phase3Letermovir (Prevymis) for CMV in Kidney and Pancreas Transplant Recipients
- phase2A Study of the Drug Letermovir (LTV) as Prevention for Recurrent of Cytomegalovirus (CMV) Infection
- phase1Pharmacokinetics of Oral Letermovir in Adults With End-Stage Kidney Disease With or Without Haemodialysis
- phase4Letermovir Use in Heart Transplant Recipients
Patent cliff
source: FDA Orange Bookfirst barrier falls
Aug 30, 2027
~1.0 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (8)
- Feb 28, 2033formulationUS 10603384
- Feb 28, 2033formulationUS 10603384
- Jan 18, 2029compositionUS RE467912.4y
- Jan 18, 2029compositionUS RE467912.4y
- Jan 18, 2029compositionUS RE467912.4y
- Jan 18, 2029compositionUS RE467912.4y
- Jan 18, 2029compositionUS RE467912.4y
- Jan 18, 2029compositionUS RE467912.4y
FDA exclusivities (32)
- Aug 30, 2031ODE-497Orphan Drug (7y)
- Aug 30, 2031ODE-495Orphan Drug (7y)
- Aug 30, 2031ODE-497Orphan Drug (7y)
- Aug 30, 2031ODE-495Orphan Drug (7y)
- Aug 30, 2031ODE-497Orphan Drug (7y)
- Aug 30, 2031ODE-495Orphan Drug (7y)
- Aug 30, 2031ODE-497Orphan Drug (7y)
- Aug 30, 2031ODE-495Orphan Drug (7y)
- Aug 30, 2031ODE-497Orphan Drug (7y)
- Aug 30, 2031ODE-495Orphan Drug (7y)
- Aug 30, 2031ODE-497Orphan Drug (7y)
- Aug 30, 2031ODE-495Orphan Drug (7y)
- Jun 5, 2030ODE-423Orphan Drug (7y)3.8y
- Jun 5, 2030ODE-423Orphan Drug (7y)3.8y
- Jun 5, 2030ODE-423Orphan Drug (7y)3.8y
- Jun 5, 2030ODE-423Orphan Drug (7y)3.8y
- Jun 5, 2030ODE*ODE*3.8y
- Jun 5, 2030ODE*ODE*3.8y
- Aug 30, 2027NPNP1.0y
- Aug 30, 2027NPPNew Product (3y)1.0y
- Aug 30, 2027NPPNew Product (3y)1.0y
- Aug 30, 2027NPPNew Product (3y)1.0y
- Aug 30, 2027NPPNew Product (3y)1.0y
- Aug 30, 2027NPNP1.0y
- Aug 2, 2026D-189New Indication (3y)
- Aug 2, 2026D-189New Indication (3y)
- Aug 2, 2026D-189New Indication (3y)
- Aug 2, 2026D-189New Indication (3y)
- Jun 5, 2026I-916Indication (3y)
- Jun 5, 2026I-916Indication (3y)
- Jun 5, 2026I-916Indication (3y)
- Jun 5, 2026I-916Indication (3y)
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 35m ago
Found something off?
comments(0)
5-min edit window · permanent after that